购物车
- 全部删除
- 您的购物车当前为空
BIIB021 (CNF2024) 是一种可口服的合成 HSP90 抑制剂,Ki 值和EC50值分别为 1.7 nM 和 38 nM。
为众多的药物研发团队赋能,
让新药发现更简单!
BIIB021 (CNF2024) 是一种可口服的合成 HSP90 抑制剂,Ki 值和EC50值分别为 1.7 nM 和 38 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 198 | 现货 | |
5 mg | ¥ 455 | 现货 | |
10 mg | ¥ 663 | 现货 | |
25 mg | ¥ 1,130 | 现货 | |
50 mg | ¥ 1,730 | 现货 | |
100 mg | ¥ 2,650 | 现货 | |
200 mg | ¥ 3,950 | 现货 | |
500 mg | ¥ 6,330 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 497 | 现货 |
产品描述 | BIIB021 (CNF2024) is an orally-available, fully synthetic inhibitor of HSP90(Ki=1.7 nM, EC50=38 nM). |
靶点活性 | HSP90:1.7 nM(Ki) |
体外活性 | 在多种移植瘤模型中,口服BIIB021能够有效抑制肿瘤的生长.在L540cy肿瘤中,BIIB021(120 mg/kg ),能够抑制细胞的增殖. |
体内活性 | 在多种肿瘤细胞中(IC50=0.06-0.31 μM),BIIB021能够抑制细胞生长,如BT474,MCF-7,N87,HT29,H1650,H1299,H69和H82。在霍奇金淋巴瘤细胞中(IC50=0.24-0.8 μM),BIIB021抑制细胞增殖 ,如KM-H2,L428,L540,L540cy,L591,L1236和DEV。BIIB021诱导Hsp90蛋白(包括HER-2,Akt和Raf-1)的降解以及热休克蛋白Hsp70和Hsp27的上调表达。 |
激酶实验 | Hsp90 Binding Assay: For fluorescence polarization competition measurements, the FITC-geldanamycin probe (20 nM) is reduced with 2 mM TCEP at room temperature for 3 hours, after which the solution is aliquoted and stored at -80 °C until used. Recombinant human Hsp90α (0.8 nM) and reduced FITC-geldanamycin (2 nM) are incubated in a 96-well microplate at room temperature for 3 hours in the presence of assay buffer containing 20 mM HEPES (pH 7.4), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 2 mM DTT, 0.1 mg/mL BGG, and 0.1% (v/v) CHAPS. Following this preincubation, BIIB021 in 100% DMSO is then added to final concentrations of 0.2 nM to 10 μM (final volume 100 μL, 2% DMSO). The reaction is incubated for 16 hours at room temperature and fluorescence is then measured in an Analyst plate reader, excitation = 485 nm, emission = 535 nm. High and low controls contained no BIIB021 or no Hsp90, respectively. The data are fit to a four-parameter curve and IC50 is generated. |
细胞实验 | A modified tetrazolium salt assay is used to measure the IC50. Tumor cells are added to 96-well plates and propagated for 24 hours before BIIB021 addition. BIIB021 is added to the plated cells. DMSO (0.03-0.003%) is included as a vehicle control. After incubation phenazine methosulfate (stock concentration 1 mg/mL) and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (stock concentration 2 mg/mL) are mixed at a ratio of 1:20 and added to each well of a 96-well plate. Reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt gives rise to a soluble formazan product that is secreted into the culture medium. After 4 hours incubation, the formazan product is quantitated spectrophotometrically at a wavelength of 490 nm. Data are acquired using SOFTmaxPRO software, and 100% viability is defined as the A490 of DMSO-treated cells stained with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (the mean A490 of cells treated with DMSO at a range of 0.03-0.003%). Percent viability of each sample is calculated from the A490 values as follows: % viability = (A490 nm sample / A490 nm DMSO-treated cells × 100). The IC50 is defined as the concentration that gives rise to 50% inhibition of cell viabilit(Only for Reference) |
别名 | CNF2024, BIIB-021, BIIB 021 |
分子量 | 318.76 |
分子式 | C14H15ClN6O |
CAS No. | 848695-25-0 |
Smiles | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C |
密度 | 1.50 g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 45 mg/mL (141.17 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容